355-OR: Glycemic Outcomes with CGM Use in Patients with Type 2 Diabetes—Real-World Analysis

Introduction 7.1 million patients with T2D in the electronic medical records. The two observation periods were: pre-index period -- 360 days prior to patients' first CGM claim; and post-index period -- 360 days after to the first CGM claim. The index date (baseline) was the date of the first CGM claim between December 27, 2019, and January 5, 2022. The primary outcome was change in HbA1c closest to 12 months after CGM acquisition. Results: The analysis included 16,410 adults with T2D (NIT, n=4,659; (BIT, n=6,182, and PIT, n=5,569) with mean baseline HbA1c 8.8% and mean age 59 years. At 12 months, the mean change in HbA1c was significant in all three subgroups compared with HbA1c levels in the pre-index period. (Figure) Conclusions: In this 12-month, real-world study, CGM use was associated with significant improvements in glucose control in both non-insulin and insulin-treated patients with T2D. Disclosure S.K. Garg: Research Support; Eli Lilly and Company. Advisory Panel; Medtronic. Research Support; Medtronic. Advisory Panel; Novo Nordisk. Research Support; DarioHealth Corp., Dexcom, Inc., Diasome. Advisory Panel; Roche Diabetes Care. I.B. Hirsch: Advisory Panel; Abbott. Research Support; Dexcom, Inc. Advisory Panel; Roche Diabetes Care. Research Support; MannKind Corporation, Tandem Diabetes Care, Inc. Advisory Panel; embecta. Research Support; Tandem Diabetes Care, Inc. Advisory Panel; Vertex Pharmaceuticals Incorporated. E. Repetto: Employee; Roche Diabetes Care. B. Ulmer: Employee; Roche Diabetes Care. C. Perkins: Employee; Roche Diabetes Care. J.K. Snell-Bergeon: None. R.M. Bergenstal: Other Relationship; Abbott. Research Support; Arkray Marketing. Consultant; Ascensia Diabetes Care, Bigfoot Biomedical, Inc., CeQur. Other Relationship; Dexcom, Inc., Eli Lilly and Company. Consultant; embecta, Hygieia. Research Support; Insulet Corporation. Consultant; MannKind Corporation. Other Relationship; Medtronic, Novo Nordisk. Consultant; Onduo LLC, Roche Diabetes Care. Other Relationship; Sanofi. Research Support; Tandem Diabetes Care, Inc. Other Relationship; UnitedHealth Group. Consultant; Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S. Funding Roche Diabetes Care